SEIKAGAKU CORPORATION Logo

SEIKAGAKU CORPORATION

A research pharma company using glycoscience to develop drugs for orthopedic & ophthalmic diseases.

4548 | T

Overview

Corporate Details

ISIN(s):
JP3414000004
LEI:
Country:
Japan
Address:
千代田区丸の内一丁目6番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Seikagaku Corporation is a research-driven pharmaceutical company specializing in glycoscience. The company engages in the research, development, manufacture, and sale of pharmaceuticals and medical devices, with a primary focus on glycoconjugates like glycosaminoglycans (GAGs). Its main therapeutic areas include orthopedic disorders and ophthalmic diseases, offering products such as joint function improving agents. Seikagaku oversees its product lifecycle from in-house drug discovery and clinical trials to regulatory approval and commercial production, leveraging its specialized expertise in the field of complex carbohydrates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 06:56
Registration Form
確認書
Japanese 8.1 KB
2025-11-12 06:55
Interim Report
半期報告書-第80期(2025/04/01-2026/03/31)
Japanese 196.8 KB
2025-06-24 08:14
Post-Annual General Meeting Information
臨時報告書
Japanese 23.0 KB
2025-06-23 06:58
Governance Information
内部統制報告書-第79期(2024/04/01-2025/03/31)
Japanese 22.6 KB
2025-06-23 06:57
Registration Form
確認書
Japanese 8.0 KB
2025-06-23 06:56
Annual Report
有価証券報告書-第79期(2024/04/01-2025/03/31)
Japanese 1.1 MB
2024-11-12 06:58
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-11-12 06:56
Interim Report
半期報告書-第79期(2024/04/01-2025/03/31)
Japanese 191.1 KB
2024-06-27 06:53
Governance Information
内部統制報告書-第78期(2023/04/01-2024/03/31)
Japanese 21.9 KB
2024-06-27 06:52
Registration Form
確認書
Japanese 8.0 KB
2024-06-27 06:51
Annual Report
有価証券報告書-第78期(2023/04/01-2024/03/31)
Japanese 1.1 MB
2024-06-25 04:10
Post-Annual General Meeting Information
臨時報告書
Japanese 23.7 KB
2024-02-14 08:57
Quarterly Report
四半期報告書-第78期第3四半期(2023/10/01-2023/12/31)
Japanese 165.1 KB
2024-02-14 08:57
Report Publication Announcement
確認書
Japanese 8.0 KB
2023-11-14 05:06
Report Publication Announcement
確認書
Japanese 8.0 KB

Automate Your Workflow. Get a real-time feed of all SEIKAGAKU CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SEIKAGAKU CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SEIKAGAKU CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alteogen Inc. Logo
Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.
South Korea
196170
ALTERITY THERAPEUTICS LTD Logo
Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.
United States of America
ATHE
Alto Neuroscience, Inc. Logo
Developing precision medicines for depression and schizophrenia using a brain biomarker platform.
United States of America
ANRO
ALUMIS INC. Logo
Develops targeted oral therapies for immune-mediated diseases using precision immunology.
United States of America
ALMS
Alvotech Holdings S.A Logo
Develops and manufactures affordable biosimilar medicines for global patient access.
Luxembourg
ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.
United States of America
ALXO
Alzamend Neuro, Inc. Logo
Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.
United States of America
ALZN
Alzinova AB Logo
Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.
Sweden
ALZ
AMARIN CORP PLC\UK Logo
Develops prescription therapies like Vascepa® to reduce cardiovascular risk for patients.
United States of America
AMRN
AMGEN INC Logo
Biotech pioneer developing innovative human therapeutics for the world's toughest diseases.
United States of America
AMGN

Talk to a Data Expert

Have a question? We'll get back to you promptly.